Nanotechnology Seminar Series
"Abraxane: Nanoparticle platform delivers improved antitumor activity"
January 24, 2006
Michael J. Hawkins, M.D.
Chief Medical Officer
American Bioscience, Inc.
Michael J. Hawkins, M.D., a medical oncologist, is the Chief Medical Officer at American Bioscience, Inc., a small privately held pharmaceutical company in Santa Monica, Calif., that is developing new formulations of anticancer drugs. Formally, Dr. Hawkins was an Associate Director of the Washington Cancer Institute at the Washington Hospital Center (1999 to 2002); the Director of the Clinical Research and Developmental Therapeutics Program at the Lombardi Cancer Center (1992 to 1999); and the Chief of the Investigational Drug Branch while at the National Cancer Institute (1984 to 1992). He was the chairman of the Cancer Advisory Panel to the National Institutes of Health's National Center for Complementary and Alternative Medicine from 2000 to 2002 and has served on advisory panels to the U.S. Food and Drug Administration. In his oncology practice he encouraged patients to pursue inner healing while being treated for their cancer.
Abraxane: Nanoparticle Platform Delivers Improved Antitumor Activity
The presentation will be on the development of nanoparticle albumin-bound (nab™) delivery platform and the efficacy and safety advantages of the first product, Abraxane (paclitaxel protein-bound particles) over conventionally formulated chemotherapeutic agents. Due in part to their small size, following IV administration the 130 nanometer particles quickly disperse as individual albumin molecules that then carry paclitaxel to the sites of tumor. The improved anti-tumor activity in metastatic breast cancer and a high level of activity in other cancers (including non-small cell lung cancer, malignant melanoma and head and neck cancers) is most likely due to the ability of Abraxane to take advantage of the natural binding characteristics of albumin, endogenous albumin-mediated transport mechanisms and localization of albumin in areas of tumor due to binding to tumor-secreted proteins.
The presentation will also include multiple other applications of the core technology platform in the pipeline to the clinic over the next 12 to 18 months.